NIKI

Niki BioSolutions, Inc. (NIKI) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Near-zero net debt and low debt-to-equity reduce refinancing pressure versus more levered peers, preserving balance-sheet flexibility despite weak profitability.

Cash conversion cycle at zero suggests working-capital discipline relative to peers with longer cash cycles, supporting liquidity even when returns remain negative.

Weaknesses

Score:

Negative ROIC indicates capital is not earning its cost, leaving NIKI structurally behind profitable peers on value creation and reinvestment capacity.

Current and quick ratios below 1.0 imply tighter short-term liquidity than peers, increasing dependence on operating cash flow and external funding.

Missing margin disclosure limits transparency, but the available return profile still signals weaker operating efficiency than peers with positive margins and returns.

Opportunities

Score:

If management converts low leverage into higher-return reinvestment, NIKI can narrow the gap with peers that already compound capital efficiently.

Working-capital efficiency can be scaled further, and peers with less disciplined cash cycles may be more exposed to liquidity drag over time.

Threats

Score:

Persistent negative ROIC raises the risk that peers with stronger economics continue to outcompete NIKI on pricing power, growth quality, and capital allocation.

Sub-1.0 liquidity ratios leave NIKI more vulnerable than peers to demand shocks or inventory build, which can force costly short-term funding.

Limited disclosed operating metrics increase uncertainty versus peers with clearer margin visibility, making competitive positioning harder to assess and potentially harder to defend.

Overall Score

Score:

NIKI’s low leverage and working-capital discipline are offset by negative returns and weak liquidity, leaving its structural positioning below stronger peer sets.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Niki BioSolutions, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →